-
Benzinga's Top Downgrades (BBT, CEVA, ALXN, BRKS)
Monday, April 25, 2011 - 8:14am | 134BB&T Corporation (NYSE: BBT) was downgraded by Oppenheimer from "outperform" to "perform." BBT's shares closed at $25.98 on Thursday. BBT's PEG ratio is 2.00. Wunderlich downgraded CEVA Inc (NASDAQ: CEVA) from “buy” to “hold.” CEVA's stock closed at $30.81 on Thursday. CEVA's trailing-twelve-...
-
Jefferies Raises PT On Biogen Idec To $120
Monday, April 25, 2011 - 7:47am | 27Jefferies & Company has raised the price target on Biogen Idec (NASDAQ: BIIB) from $100 to $120 and maintains its Buy rating.
-
Piper Jaffray Reports 1Q Earnings On ALXN
Monday, April 25, 2011 - 7:45am | 183Piper Jaffray, reporting 1Q earnings results on Alexion Pharmaceuticals (NASDAQ: ALXN), is maintaining its Overweight rating and its $119 price target. According to Piper Jaffray, “Alexion's 1Q11 EPS of $0.59 was $0.08 above Street as Soliris sales growth remains strong (+41% y/y) despite...
-
Needham Downs ALXN To Hold
Monday, April 25, 2011 - 7:41am | 39Analysts at Needham downgraded Alexion Pharmaceuticals Inc (NASDAQ: ALXN) from “buy” to “hold.” ALXN's shares closed at $99.76 on Thursday. More Analyst Ratings here
-
Pharmasset Reports Q2 EPS of $(0.55) vs. $(0.65)
Monday, April 25, 2011 - 7:30am | 16Pharmasset (NASDAQ: VRUS) Reports Q2 EPS of $(0.55) vs. $(0.65)
-
Jefferies Raises PT on Alexion Pharmaceuticals To $87
Monday, April 25, 2011 - 6:58am | 27Jefferies & Company has raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) from $77 to $87 and maintains its Hold rating.
-
Top 5 S&P 500 worst performers for the week – IRM, GILD, HOG, KEY and DV
Sunday, April 24, 2011 - 6:21am | 1285The S&P 500 underperformed the Dow Jones but was pretty much equal with the NASDAQ composite. The Dow Jones Industrial Index ended the trading week at 12506, which represents 1.33% from previous week, the NASDAQ on the other hand closed the week at 2820.16 representing 2.01% from its previous...
-
Market Perspective & Perception 04-21-2011
Thursday, April 21, 2011 - 6:08pm | 918Cusick's Corner I had a great conversation with my dad this afternoon about Perspective & Perception and why it would be a great topic for a Corner -- so here I go. Perspective is how things appear, the reality. What we know is that earnings have been solid, economic data mixed and global...
-
Claims Data Puts Brakes on Run But Market Holds 04-21-2011
Thursday, April 21, 2011 - 2:45pm | 885Cusick's Corner Earnings continue to boost the market into the Midday. The Claims data, 403K, did put the brakes on the run from overnight but the market has held. The volume has been lighter than average at this stage but that might be because many desks are clearing out for the long weekend. The...
-
Negative Rumors About INCYTE Circulate (INCY)
Thursday, April 21, 2011 - 2:01pm | 85Unconfirmed Negative rumors circulating at INCYTE (NASDAQ: INCY). Hearing Analyst Downgrade This article may include mentions of rumors, chatter, or unconfirmed information. Readers should beware that while unconfirmed information may be correlated with increased volatility in securities, price...
-
Biotech/Pharma Investor Spotlight; Profile for BioSante Pharmaceuticals and its Lead Products, LibiGel® and Bio-T-Gel™
Thursday, April 21, 2011 - 12:02pm | 1206Point Roberts, WA - April 21, 2011 (Investorideas.com Newswire) Investorideas.com, a leader in sector stock research including biotech and pharma stocks, profiles BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and its lead products, LibiGel® (testosterone gel) and Bio-T-Gel. Hi-lights are featured...
-
Options Brief: Regeneron Pharmaceuticals, Inc. (REGN)
Thursday, April 21, 2011 - 11:53am | 73Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) are higher on the session by 0.52%, trading at $49.94. Overall put volume is now running at 3.14x the daily average, with 30% of all puts traded being purchases on the offer. 1,320 contracts have traded on the session so far. Regeneron...
-
Calls Purchased on Orexigen Therapeutics, Inc (OREX)
Thursday, April 21, 2011 - 10:45am | 140Shares of Orexigen Therapeutics, Inc (NASDAQ: OREX) are higher on the session by 10.64%, currently trading at $3.23. The stock has been moving largely lower over the past five months and is currently trading below the 50-day and 200-day moving averages. Options traders are buying calls on the...
-
Options Brief: Cell Therapeutics (CTIC)
Thursday, April 21, 2011 - 10:39am | 93Shares of Cell Therapeutics (NASDAQ: CTIC) are lower on the session by 1.67%, trading at $0.3835. Overall call volume is now running at 6.10x the daily average, with 74% of all calls traded being purchases on the offer. 8,893 contracts have traded on the session so far. Cell Therapeutics, Inc....
-
Benzinga's Volume Movers (BIIB, SCSS, TZOO, PENN)
Thursday, April 21, 2011 - 10:31am | 157Biogen Idec Inc (NASDAQ: BIIB) shares moved up 22.96% to $106.45 at 10:30 am. The volume of BIIB shares traded was 1010% higher than normal. BIIB reported upbeat Q1 results. Select Comfort Corporation (NASDAQ: SCSS) shares rose 23.70% to $16.42. The volume of SCSS shares traded was 607% higher...